Mindmed reports first quarter 2022 financial results and business highlights

- advanced clinical programs for three lead drug candidates - - strengthened leadership team with the appointment of francois lilienthal, md as chief commercial officer - - cash runway through key clinical readouts in 2023 and into 2024 - - company to host conference call today at 8:30 am et - new york , may 16, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (the "company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended march 31, 2022. "the outset of 2022 was marked by significant progress across all aspects of the company that propelled our business forward, as we continued to advance and de-risk our three lead product candidates: mm-120 for the treatment of generalized anxiety disorder, mm-402 for the treatment of core symptoms of autism spectrum disorder, and mm-110 for the management of opioid use disorder," said robert barrow, chief executive officer and director of mindmed.
MNMD Ratings Summary
MNMD Quant Ranking